Compare Inovio Pharmaceuticals Inc (INO) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PAGSEG Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while PAGSEG Inc trades at $11.16 (market cap $2.94B). The key difference: PAGSEG Inc is far larger — about 26.2× Inovio Pharmaceuticals Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and PAGSEG Inc for 26 Days on average.
| INO | PAGS | |
|---|---|---|
Market Cap | $112.19M | $2.94B |
Volume | 3,201,278 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $2.60 | $12.00 |
52-Week Low | $0.66 | $8.44 |
Typical Hold Time | 43 Days | 26 Days |
Enterprise Value | $83.51M | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
PagSeguro Digital (PAGS) trades at $10.68, up 1.62% with strong bullish technical signals from moving averages. The stock shows attractive valuation metrics with P/E of 7.1 and P/S of 0.74, while maintaining solid profitability with 10.45% net margin and 14.54% ROE. Recent Q2 2026 earnings beat expectations at $0.41 per share, and the company announced a $0.28 dividend for H2-2026, supporting investor returns.
PAGS presents value opportunity with discounted valuation and dividend yield, though faces execution risks amid Brazilian macroeconomic challenges. Analyst consensus remains strongly bullish with 62.5% buy ratings and $10.70 price target, but investors should monitor credit portfolio performance and interest rate sensitivity in current high-rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
